SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

RAD: 12-36036- -28 **FECHA**: 2016-03-17 09:05:16
DEP: 2020 DIRECCION DE NUEVAS CREACIONES **EVE:** 378 FASE NACIONAL INCLUIDO CAPITULO I
TRA: 11 PCT-PATENTE DE INVENCION CAPITULOS I Y II **FOLIOS**: 6
ACT: 519 TRASLADOINFORME

DIRECCIÓN DE NUEVAS CREACIONES

2020
Bogotá, D.C.,

Abogado(a)/Señor(a)
ANDREA TOBOS MATEUS

Asunto: Radicación: 12-36036- -28
Trámite: 11
Evento: 378
Actuación: 519
Oficio: 2951
Folios: 6

Patente de Invención	**X**			Patente de Modelo de Utilidad	
Vía Nacional					
Vía PCT (Fase Nacional)	**X**	Capítulo I	**X**	Capítulo II	
No. Solicitud Internacional	PCT/US2010/043586				
Fecha de Presentación Internacional	28/07/2010				

Como resultado del examen de fondo realizado, con fundamento en el Artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se comunica:

1. Documentos estudiados

Descripción:	Radicado N° 12-036036-00000-0000	01/Marzo/2012
Reivindicaciones:	N° 12-036036-00000-0000	01/Marzo/2012
	N° 12-036036-00014-0000	29/Octubre/2013
	N° 12-036036-00017-0000	03/Octubre/2014
	N° 12-036036-00021-0000	29/Diciembre/2014
	N° 12-036036-00024-0000	09/Junio/2015
Respuesta de la solicitante:	N° 12-036036-00017-0000	03/Octubre/2014
	N° 12-036036-00021-0000	29/Diciembre/2014
Prioridad:	US 61/229,195 US 61/303,044 US 61/317,513 US 61/333,372 US 61/359,338	28/Julio/2009 10/Febrero/2010 25/Marzo/2010 11/Mayo/2010 28/Junio/2010

2. Análisis de la Prioridad

Se acepta la reivindicación de prioridad porque ésta solicitud fue presentada dentro del plazo establecido (Art. 9 D 486) y su contenido técnico corresponde con el de la prioridad reivindicada.

3. Objeto de la invención

De acuerdo con lo establecido en el numeral 1.2.2.2 del capítulo primero del Título X de la Circular Única para efectos del examen de patentabilidad, se tendrá en cuenta la tasa pagada por la solicitante al momento de comenzar el examen para las reivindicaciones adicionales; esto es que cuando la solicitud contenga más de diez (10) reivindicaciones y no se haya pagado la tasa complementaria, sólo se estudiarán las cubiertas por la tasa pagada. Se solicita se allegue al expediente el recibo de pago de la modificación voluntaria y reivindicaciones adicionales. En el presente caso se estudiarán las reivindicaciones1 a 36 del capítulo reivindicatorio (Radicado 12-036036-00024-0000).

Título de la solicitud: “COMPOSICIONES Y MÉTODOS PARA TRATAR LA ENFERMEDAD DE GAUCHER”

El problema planteado en esta solicitud consiste en la necesidad de suministrar composiciones útiles en el tratamiento de la enfermedad de Gaucher que produzcan menos eventos adversos.

Para resolver este problema técnico la solicitud en estudio proporciona una composición que comprende velaglucerasa, una sal tampón y agentes estabilizantes.

El objeto de la presente solicitud se relaciona con la Clasificación Internacional de Patentes (CIP): A61K38/46 y A61K38/47.

4. De la solicitud de patente

Titulo

El título incluye la expresión “(…) *para tratar* (…)” la cual refiere un método de tratamiento y de acuerdo con el artículo 20 (literal d) de la Decisión 486 de 2000 los métodos de tratamiento constituyen una excepción a la patentabilidad, por lo anterior se sugiere eliminar la mencionada referencia e incluir las características esenciales de la invención.

Reivindicaciones (Art 30 D 486, Art 22 PCT)

Las reivindicaciones 1-7, 19-28 y 30-35 no son claras porque definen a los excipientes de formulación en términos de su función dentro de la composición o por su clasificación química a través de las siguientes expresiones “un lioprotector”, “un agente tampón”, “un agente estabilizante”, “carbohidrato”, “diluyente estéril”, “agente bacteriano o antifúngico”, “agente antioxidante”, agente quelante”; “agente ajuste de tonicidad”, “disolvente o medio de dispersión”, “surfactante”, “agente isotónico”, “azúcar”, “polialcohol” y “agente que retrasa la absorción”; se recuerda que los excipientes de formulación se deben definir en términos de su nombre común especificando para cada uno de éstos su proporción. Se sugiere hacer las aclaraciones necesarias.

Las reivindicaciones 9-10 no son claras porque reclaman el porcentaje de humedad, el cual corresponde a un resultado a alcanzar y no definen a la composición, puesto que las reivindicaciones incluirían no sólo la solución propuesta por la solicitante, sino todas las alternativas presentes o futuras que lleguen a ese resultado. Se sugiere

reemplazarlo por las características esenciales, estructurales o funcionales, que contribuyen a la obtención de ese efecto.

Las reivindicaciones 13-16 reclaman una composición reconstituida, pero dichas cláusulas no pueden ser motivo de estudio de patentabilidad comoquiera que no son estables y no se comercializan de esa forma, es decir, no cumplen el requisito de aplicación industrial (Art. 19 D. 486); se sugiere hacer las precisiones necesarias.

Las reivindicaciones 17-18 reclaman la vía de administración de la composición, se recuerda que las composiciones farmacéuticas se definen en términos de sus ingredientes y proporciones y no por su ruta de administración, se sugiere hacer las precisiones necesarias.

La reivindicación 29 no es clara porque hace referencia al nombre Cremophor EL™ , que es una marca registrada y por tanto no definen al producto porque su composición puede cambiar con el paso del tiempo aunque conserve el mismo nombre. Se sugiere aclarar cuáles son las características del producto en cuestión.

Se requiere a la solicitante hacer las aclaraciones necesarias.

5. Determinación del Estado de la Técnica

El estado de la técnica se determinó con base en la fecha de presentación de la solicitud de prioridad: julio 28 de 2009 y se encontraron los siguientes documentos que anticipan el objeto de esta solicitud:

Ítem	Documento	Título	Fecha de Publicación
D1	Shire Limited Supplement prospectus investors	"Supplement to the Prospectus in respect of Introduction of up to 700,000,000 Ordinary Shares of 5 pence each to the Official List"	29/Abril/2009
D2	ES2391657	"Composiciones estabilizadas de proteínas que tienen un resto tiol libre"	05/Noviembre/2008

El documento D1[(1)] divulga a la enzima alfa velaglucerasa (GA-GCB) como prospecto para un desarrollo exitoso de productos manufacturados (Pág.2, Último Párrafo).

El documento D2[(2)] divulga composiciones que comprenden proteínas glucocerebrosidas incluidas en una matriz conformada por sales de citrato, polisorbato 20 y sacarosa; en donde estas son útiles en tratamiento de la enfermedad de Gaucher (Pág.16, Rvs. 1-10 y Pág. 17, Rvs. 35-36).

6. Examen de Patentabilidad (Art 14 D486)

Nivel inventivo (Art 18 D486)

La reivindicación 1 consiste en: *"Una composición farmacéutica que comprende velaglucerasa, un lioprotector, una sal tampón y agente estabilizante"* (Radicado Nº. 12-036036-00024-0000).

Comparación de las características técnicas esenciales, con las del estado de la técnica:

Características esenciales	D1	D2
Composición farmacéutica que comprende:	No menciona	Composición farmacéutica que comprende: (Pág.16, Rv. 1)

1. http://investors.shire.com/~/media/Files/S/Shire-IR/events/year-2008/supplement-prospectus.pdf
2. www.google/patents/ ES2391657

Velaglucerasa	Velaglucerasa (Pág 2, Último Párrafo)	Proteína (GCB) glucocerobrosidasa (Pág.16, Rv. 1)
Lioprotector	No menciona	Sacarosa (Pág.16, Rv. 1)
Sal Tampón	No menciona	Citrato sal (Pág.16, Rv. 10)
Agente estabilizante	No menciona	Polisorbato 20 (Pág. 16,Rv. 10)

El documento D1 se considera el estado de la técnica más cercano a la invención definida en la reivindicación 1 porque divulga a la enzima alfa velaglucerasa (GA-GCB) como prospecto para un desarrollo exitoso de productos manufacturados (Pág.2, Último Párrafo).

La diferencia entre la composición, definida en la reivindicación 1 y el compuesto revelado en el documento D1 consiste en que la composición reclamada incluye a la proteína Velaglucerasa dentro de una matriz conformada por excipientes de formulación (Lioprotector, sal tampón y agente estabilizante).

No hay evidencia de un efecto técnico sorprendente porque la descripción presenta la comparación del efecto de la velaglucerasa versus imiglucerasa sobre el volumen del hígado y del bazo y sobre la concentración de hemoglobina y concentración de plaquetas, los cuales no son significativamente diferentes (Ver Tabla 24).

Por lo tanto, el problema técnico objetivo que pretende resolver esta invención se puede formular así: cómo proporcionar composiciones alternativas a las reveladas en el documento D1 que comprendan a la proteína velaglucerasa, que sean útiles en el tratamiento de la enfermedad de Gaucher.

Sin embargo, el documento D2 revela composiciones que comprenden proteínas glucocerebrosidas incluidas en una matriz conformada por sales de citrato, polisorbato 20 y sacarosa; en donde estas son útiles en tratamiento de la enfermedad de Gaucher.

En consecuencia, la persona del oficio normalmente versada en la materia, incluiría a la proteína revelada en el documento D1 en una matriz de excipientes de acuerdo con lo divulgado en el documento D2, para llegar así al objeto de la reivindicación 1 de la solicitud. Por lo cual se considera obvia.

Puesto que las reivindicaciones dependientes 2-35 no mencionan características inventivas adicionales tampoco se pueden considerar inventivas.

La reivindicación 36 define "*Una composición que comprende velaglucerasa, ácido cítrico, polisorbato 20, (…)*" (Radicado Nº. 12-036036-00024-0000) y establece la adición de sacarosa en la matriz de excipientes de formulación, pero no se observa un efecto técnico asociado a la adición del mencionado excipiente, razón por la cual dicha característica tampoco se puede considerar inventiva.

Aplicación industrial (Art 19 D 486)

Las reivindicaciones 13-16 reclaman una composición reconstituida, pero dichas cláusulas no cumplen el requisito de aplicación industrial comoquiera que no son estables y no se comercializan de esa forma.

7. Conclusión

Los requisitos de Patentabilidad de la presente solicitud están afectados así:

Ítem	Documento	Reivindicaciones afectadas	Requisito que afecta
D1	Shire Limited Supplement prospectus investors	1-36	Nivel inventivo
D2	ES2391657	1-36	Nivel inventivo

En cumplimiento del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le indica que debe dar respuesta dentro del término de sesenta (60) días contados a partir del día siguiente de la fecha de notificación de la presente comunicación. En caso de no dar respuesta al presente requerimiento, o si a pesar de la respuesta subsistieran los impedimentos para la concesión, se denegará la patente.

Si como respuesta a este requerimiento el solicitante llegara a modificar: i) el capítulo reivindicatorio, ii) la descripción de la invención a proteger, iii) o presente un nuevo capítulo reivindicatorio, no deberá pagar la tasa de modificación voluntaria pero sí la correspondiente a la tasa de examen de patentabilidad para que se estudie la materia modificada. En todo caso, el número de requerimientos por no patentabilidad estará supeditado a que el término del estudio de patentabilidad no sea superior a 18 meses, contados desde la publicación de la solicitud de patente de invención. Adicionalmente, se le recuerda al solicitante que si como respuesta a este requerimiento llegara a modificar el capítulo reivindicatorio y éste contenga más de diez (10) reivindicaciones deberá pagar la tasa por reivindicación adicional.

Se invita al solicitante se sirva indicar, si así lo considera, su renuncia al término faltante de sesenta (60) días para dar respuesta a este requerimiento y presentarla por escrito.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo quinto del título primero de la Circular Única No. 10 de 2001.

JOSÉ LUIS SALAZAR LÓPEZ
Director de Nuevas Creaciones (c)

El anterior requerimiento fue notificado por fijación en lista, de fecha 2016-03-22

Elaboró: German Antonio Clavijo Cohen
Revisó: Olga Rosa Gonzalez Fonseca

INFORME DE BÙSQUEDA DE PATENTES PARA EL No de Radicación: 12-036036						
CRITERIOS PARA LA BÙSQUEDA (anexar pantallazo o reporte en PDF, junto con los boleanos utilizados)						
Palabras clave utilizadas	Supplement velaglucerase velaglucerase					
CLASIFICACIONES INTERNACIONALES UTILIZADAS PARA LA BÚSQUEDA	A61K38/46 y A61K38/47					
BASES DE DATOS CONSULTADAS.						
Google/patents						
USPTO						
PatBase						
INFORMES DE EXÁMENES REALIZADOS EN OTRAS OFICINAS (documentos patentes, literatura no patente etc…)						
Oficina	Fecha del examen o de reporte de búsqueda de documentos	Anterioridades encontradas para el examen o reportados en el examen de búsqueda(relacionarlos todos)	Reiv. afectadas	RELEVANCIA (requisito que afecta)	FUERON TENIDOS EN CUENTA PARA EL EXAMEN EN LA OFICINA COLOMBIANA	
					SI	NO
EUROPEA	10/02/2011	Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, (20030701), vol. 278, no. 1-2,	1-36	Nivel inventivo		X
		"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (19990315), vol. 93, no. 6, ISSN 0006-4971, PAGE 2081 - 2088	1-36	Nivel inventivo		X
		aucher's disease", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, (20090201), vol. 34, no. 2, doi:10.1358/DOF.2009.034.02.1336030, ISSN 0377-8282, PAGE 147 - 149, XP008120613 [Y] 1-14 p. 148	1-36	Nivel inventivo		X
		Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment", NATURE BIOTECHNOLOGY, (20080801), vol. 26, no. 8, doi:10.1038/nbt.1484, ISSN 1087-0156, PAGE 901 - 908, XP055056885 [Y] 1-14 p. 904 , fig. 1	1-36	Nivel inventivo		X
DOCUMENTOS ADICIONALES ENCONTRADOS POR EL EXAMINADOR DE ACUERDO A LOS CRITERIOS DE BÙSQUEDA.						
Shire Limited Supplement prospectus investors						
ES2391657						

BÚSQUEDA DE SECUENCIAS Número de depósito / patente y N° de secuencia % de identidad					
SEQ ID NO (de la solicitud)	NCBI	The Lens	EMBL-EBI	DDJB	Genome Quest
	No aplica				

CRITERIOS DE BÚSQUEDA / UNIDAD DE INVENCIÓN (Pantallazos)



Stable pharmaceutical compositions

image not available

www.google.com.co/.../WO2012001641... - Traducir esta página
Solicitada - Presentada el 29 Jun 2011 - Fecha de publicación: 5 Ene 2012 - Olga Abian - Actelion Pharmaceuticals Ltd
A liquid pharmaceutical composition according to claim 6 or 7, wherein the enzyme is **velaglucerase** alfa. 10. A liquid pharmaceutical ...
Descripción general - Resultados relacionados - Foro de debate

Compositions and methods for treating gaucher disease

image not available

www.google.com.co/.../EP2459212A1?cl... - Traducir esta página
Solicitada - Presentada el 28 Jul 2010 - Fecha de publicación: 6 Jun 2012 - Peter F. Daniel - Shire Human Genetic Therapies
velaglucerase is administered at a dose of 2.5 U/kg to 60 U/kg. In some embodiments, the **velaglucerase** is administered every other week by ...
Descripción general - Resultados relacionados - Foro de debate

Mannose receptor c type 1 (mrc1) codon optimized cell line ...

image not available

www.google.com.co/.../EP2595651A2?cl... - Traducir esta página
Solicitada - Presentada el 19 Jul 2011 - Fecha de publicación: 29 May 2013 - Juan Ruiz - Shire Human Genetic Therapies, Inc.
The method of claim 72, wherein **velaglucerase** is administered at a dose of about 2.5 to about 60 U/kg. 75. The method of claim 72, wherein ...
Descripción general - Resultados relacionados - Foro de debate

This document comprises a supplementary prospectus relating to New Shire for the purpose of Prospectus Rule 3.4 and has been prepared in accordance with the Prospectus Rules made under section 73A of the Financial Services and Markets Act 2000, as amended (**"FSMA"**). This document has been approved as a supplementary prospectus under section 87A of FSMA. A copy of this document has been filed with the Financial Services Authority and made available to the public as required by Prospectus Rule 3.2.

This document is supplemental to and must be read in conjunction with the Prospectus. Save as disclosed in this document, since the publication of the Prospectus there have been no other significant new factors, material mistakes or inaccuracies relating to the information included in the Prospectus. YOU SHOULD READ THIS DOCUMENT AND THE PROSPECTUS IN THEIR ENTIRETY, AND IN PARTICULAR THE SECTION OF THE PROSPECTUS HEADED "RISK FACTORS".

Except where the context otherwise requires, capitalised terms used in this document have the meanings ascribed to them in the "Definitions" and "Glossary of Scientific Terms and Abbreviations" sections of the Prospectus found on pages 311 to 317 of the Prospectus.

To the extent that there is any inconsistency between a statement in this document and a statement in the Prospectus, the statement in this document will prevail.

The Directors, whose names appear on page 6 of this document, and New Shire, whose registered office is 22 Grenville Street, St Helier, Jersey JE4 8PX, are responsible for the information contained herein. The Directors and New Shire declare that, having taken all reasonable care to ensure that such is the case, the information contained in this document is, to the best of their knowledge, in accordance with the facts and contains no omission likely to affect its import.

Application will be made to the UK Listing Authority for the New Shire Ordinary Shares to be admitted to the Official List and to the London Stock Exchange for the New Shire Ordinary Shares to be admitted to trading on the London Stock Exchange's main market for listed securities, which together, under the Listing Rules of the UK Listing Authority, will constitute official listing on a stock exchange. If the Scheme proceeds as presently envisaged, it is expected that admission to the Official List of the New Shire Ordinary Shares will become effective, and that dealings in New Shire Ordinary Shares on the London Stock Exchange's main market for listed securities will commence, on May 23, 2008.

No New Shire Ordinary Shares have been marketed to, nor are any available for purchase or exchange, in whole or in part, by, the public in the United Kingdom or elsewhere in connection with the admission to the Official List. This document does not constitute an offer or invitation to any person to subscribe for or purchase any securities in New Shire.

Shire

Shire Limited

(Incorporated in Jersey with registered number 99854)

Supplement to the Prospectus in respect of Introduction of up to 700,000,000 Ordinary Shares of 5 pence each to the Official List

Sponsored by Morgan Stanley & Co. International plc

Morgan Stanley & Co. International plc is acting exclusively for Old Shire and New Shire and no-one else in connection with the listing of the New Shire Ordinary Shares and is not, and will not be, responsible to anyone other than Old Shire and New Shire for providing the protections afforded to clients of Morgan Stanley & Co. International plc or for providing advice in connection with the listing of the New Shire Ordinary Shares.

The date of this document is April 29, 2008.

The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and therefore this document may not be distributed or published in any jurisdiction except under circumstances which result in compliance with any applicable laws and regulations. Persons into whose possession this document comes should inform themselves about and observe such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

THIS DOCUMENT DOES NOT CONSTITUTE AN INVITATION OR OFFER TO SELL OR THE SOLICITATION OF AN INVITATION OR OFFER TO BUY ANY SECURITY. NONE OF THE SECURITIES REFERRED TO IN THIS DOCUMENT SHALL BE SOLD, ISSUED, EXCHANGED OR TRANSFERRED IN ANY JURISDICTION IN CONTRAVENTION OF APPLICABLE LAW.

Securities may not be offered or sold in the United States unless they are registered under the US Securities Act of 1933, as amended, or are exempt from such registration. The New Shire Ordinary Shares will not be, and are not required to be, registered with the US Securities and Exchange Commission under the US Securities Act of 1933, as

amended, in reliance on the exemption from registration provided by Section 3(a)(10) thereof. **Neither the SEC nor any other US federal or state securities commission or regulatory authority has approved or disapproved the New Shire Ordinary Shares or passed on the adequacy of this document. Any representation to the contrary is a criminal offence in the United States.**

INFORMATION FOR UNITED STATES SHAREHOLDERS

In the United States, this document is being furnished to Old Shire Shareholders and registered holders of Old Shire ADSs solely to explain the Proposals and describe the action recommended to be taken by Old Shire Shareholders in relation to the Court Meeting and EGM. This document is personal to each Old Shire Shareholder and does not constitute an offer to any other person or to the public generally to subscribe for or otherwise acquire New Shire Ordinary Shares. This document is not an offer of securities for sale in the United States. The New Shire Ordinary Shares to be issued to Old Shire Ordinary Shareholders in connection with the Scheme will not be, and are not required to be, registered with the SEC under the US Securities Act in reliance upon the exemption from the registration requirements of the US Securities Act provided by Section 3(a)(10) of that act. For the purpose of qualifying for the Section 3(a)(10) exemption with respect to the New Shire Ordinary Shares issued pursuant to the Scheme, Old Shire will advise the High Court that it will rely on the Section 3(a)(10) exemption based on the High Court's sanctioning of the Scheme, which will be relied upon by Old Shire as an approval of the Scheme following a hearing on its fairness to Old Shire Ordinary Shareholders at which hearing all such Old Shire Ordinary Shareholders will be entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification has been or will be given to all such shareholders.

NOTICE TO NEW HAMPSHIRE RESIDENTS

NEITHER THE FACT THAT A REGISTRATION STATEMENT OR AN APPLICATION FOR A LICENCE HAS BEEN FILED UNDER CHAPTER 421-B OF THE NEW HAMPSHIRE REVISED STATUTES WITH THE STATE OF NEW HAMPSHIRE NOR THE FACT THAT A SECURITY IS EFFECTIVELY REGISTERED OR A PERSON IS LICENSED IN THE STATE OF NEW HAMPSHIRE CONSTITUTES A FINDING BY THE SECRETARY OF STATE OF NEW HAMPSHIRE THAT ANY DOCUMENT FILED UNDER RSA 421-B IS TRUE, COMPLETE AND NOT MISLEADING. NEITHER ANY SUCH FACT NOR THE FACT THAT AN EXEMPTION OR EXCEPTION IS AVAILABLE FOR A SECURITY OR A TRANSACTION MEANS THAT THE SECRETARY OF STATE HAS PASSED IN ANY WAY UPON THE MERITS OR QUALIFICATIONS OF, OR RECOMMENDED OR GIVEN APPROVAL TO, ANY PERSON, SECURITY OR TRANSACTION. IT IS UNLAWFUL TO MAKE, OR CAUSE TO BE MADE TO ANY PROSPECTIVE PURCHASER, CUSTOMER OR CLIENT, ANY REPRESENTATION INCONSISTENT WITH THE PROVISIONS OF THIS PARAGRAPH.

Cautionary statement regarding forward-looking statements

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire Group's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA® (Human TGFβ3) and velaglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the launch and establishment in the market of VYVANSE™ (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not limited to, the impact of those on the Shire Group's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire Group's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV™ (guanfacine extended release) (ADHD); Old Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Old Shire's filings with the Securities and Exchange Commission, including

Old Shire's Annual Report on Form 10-K for the year to December 31, 2007. Except as required by the Listing Rules, the Disclosure and Transparency Rules, the Prospectus Rules, the London Stock Exchange or otherwise required by law, New Shire expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in New Shire's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Enforceability of judgments

Old Shire is a public limited company incorporated under the laws of England and Wales and New Shire is a public company limited by shares incorporated under the laws of Jersey. Certain of the Directors of New Shire and Old Shire are citizens or residents of countries other than the United States. Substantially all or a significant portion of the assets of such persons and a significant proportion of the assets of Shire Group are located outside the United States. As a result, it may not be possible to effect service of process within the United States upon such persons or New Shire and/or Old Shire, or to enforce against them judgments of US courts, including judgments predicated upon civil liabilities under the securities laws of the United States or any state or territory within the United States. There is substantial doubt as to the enforceability in the United Kingdom in original actions or in actions for enforcement of judgments of US courts, based on the civil liability provisions of US federal securities laws.

Notice to US Investors

Certain of the financial information included in this document and the Prospectus has been prepared in accordance with accounting standards applicable in the United Kingdom that may not be comparable to the financial statements of US companies. US generally accepted accounting principles (US GAAP) differ in certain significant respects from International Financial Reporting Standards (IFRS). Certain of the financial information in this document and the Prospectus has not been audited in accordance with auditing standards generally accepted in the United States or the auditing standards of the Public Company Accounting Oversight Board (United States).

This document is supplemental to, and should be read in conjunction with, the Prospectus dated 16 April 2008 which is available on Shire Group's website at www.shire.com.

PART 1 – DECISION ON APPROVAL OF THE VYVANSE ADULT INDICATION, ACQUISITION OF METAZYME™ AND FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2008

Following the publication of the Prospectus:

(a) on April 23, 2008, Old Shire announced the FDA approval of Old Shire's sNDA for the use of VYVANSE in the treatment of ADHD in adults;

(b) on April 24, 2008, Old Shire announced the acquisition of arylsufatase–A ("ASA"), an enzyme replacement therapy ("ERT") in Phase 1-2 clinical trials, being investigated for the treatment of Metachromatic Leukodystrophy ("MLD"), from Zymenex A/S ("Zymenex"); and

(c) on April 25, 2008, Old Shire announced the unaudited financial results of Shire Group for the three months ended March 31, 2008.

The Directors regard this information as comprising significant new factors relating to information contained in the Prospectus and accordingly have prepared and published this document in accordance with section 87G of FSMA, the Prospectus Rules and Listing Rules. Save as disclosed in this Part 1, there is no further information that is required to be disclosed in this supplementary prospectus pursuant to section 87G of FSMA.

1. Decision with respect to approval of the VYVANSE adult indication

The full text of the announcement dated April 23, 2008, relating to the FDA approval of Old Shire's sNDA for the use of VYVANSE in the treatment of ADHD in adults is hereby incorporated by reference into, and forms part of, this document. A copy of the full text of the announcement has been filed with the UK Listing Authority and is available on Shire Group's website at www.shire.com.

2. Acquisition of clinical candidate ASA, currently known as METAZYME™, a Phase 1-2 product, being investigated for the treatment of MLD

The full text of the announcement dated April 24, 2008, relating to the acquisition by Old Shire of ASA (an ERT in Phase 1-2 clinical trials for MLD) from Zymenex is hereby incorporated by reference into, and forms part of, this document. A copy of the full text of the announcement has been filed with the UK Listing Authority and is available on Shire Group's website at www.shire.com.

3. Financial results of Shire Group for the three months ended March 31, 2008

The full text of the announcement dated April 25, 2008, containing the unaudited US GAAP financial results of Shire Group for the three months to March 31, 2008, is hereby incorporated

by reference into, and forms part of, this document. A copy of the full text of the announcement has been filed with the UK Listing Authority and is available on Shire Group's website at www.shire.com.

The following list is intended to enable investors to easily identify specific items of information which have been incorporated by reference into this document and the Prospectus:

FDA decision with respect to approval of the VYVANSE adult indication	Public announcement to a RIS made by Old Shire on April 23, 2008
Acquisition of clinical candidate ASA (currently known as METAZYME™)	Public announcement to a RIS made by Old Shire on April 24, 2008
Financial results for Shire Group for the three months ended March 31, 2008	Public announcement to a RIS made by Old Shire on April 25, 2008

Any information that is incorporated by reference into documents which are incorporated into this document is not incorporated by reference into this document.

PART 2 – ADDITIONAL INFORMATION

1. Responsibility Statement

The Directors, whose names and principal functions are set out in paragraph 2 below, and New Shire accept responsibility for the information contained in this document. To the best of the knowledge of the Directors and New Shire (who have each taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and contains no omissions likely to affect its import.

2. Directors

The names and principal functions of the Directors are as set out below:

Director	Position
Dr James Cavanaugh	Chairman
Mr Matthew Emmens	Chief Executive
Mr Angus Russell	Finance Director
Dr Barry Price	Non-Executive Director
Mr Robin Buchanan	Non-Executive Director
Mr David Kappler	Non-Executive Director
Mr Patrick Langlois	Non-Executive Director
Dr Jeffrey Leiden	Non-Executive Director
Ms Kate Nealon	Non-Executive Director
Mr David Mott	Non-Executive Director
Dr Michael Rosenblatt	Non-Executive Director

Dr Michael Rosenblatt became a director of New Shire on April 28, 2008.

The business address of each of the Directors is 22 Grenville Street, St Helier, Jersey JE4 8PX.

3. Documents available for inspection

In addition to those documents set out in paragraph 21 of Part 5 of the Prospectus, copies of this document and all the information incorporated by reference herein may be inspected at the offices of New Shire's solicitors, Slaughter and May, at One Bunhill Row, London EC1Y 8YY and the registered office of New Shire at 22 Grenville Street, St Helier, Jersey JE4 8PX during normal business hours on any day (Saturdays, Sundays and public holidays excepted) until close of business on the day of the Court Meeting and the EGM and will also be available for inspection for 15 minutes before and during the Court Meeting and the EGM.